Biogen
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
With a market cap of 24.83B, Biogen(BIIB) trades at $169.32. The stock has a price-to-earnings ratio of 16.26.
As of 2026-01-15, Biogen(BIIB) stock has fluctuated between $165.60 and $178.41. The current price stands at $169.32, placing the stock +2.2% above today's low and -5.1% off the high.
The Biogen(BIIB)'s current trading volume is 3.64M, compared to an average daily volume of 1.74M.
During the past year, Biogen(BIIB) stock moved between $110.04 at its lowest and $190.20 at its peak.
During the past year, Biogen(BIIB) stock moved between $110.04 at its lowest and $190.20 at its peak.
BIIB News
(RTTNews) - Biogen Inc. (BIIB) expects its fourth-quarter 2025 results to include approximately $222 million in acquired in-process research and development (IP...
In a regulatory filing, the company stated, “Biogen (BIIB) expects that its GAAP and non-GAAP results for the fourth quarter of 2025 will include acquired in-pr...
Biogen recently received European Commission marketing authorization for a high-dose SPINRAZA regimen to treat 5q spinal muscular atrophy, covering rapid-loadin...
Analyst ratings
51%
of 37 ratingsMore BIIB News
Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Biogen and increased the price target to $165.00 from $150.00. Claim 70% Off TipRanks Premiu...
Biogen Inc. (BIIB) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools...
Biogen (BIIB) announced the European Commission has granted marketing authorization for a high dose regimen of SPINRAZA which is comprised of 50 mg/5 mL and 28...
Biogen Inc. (BIIB) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Study Overview This Phase 1 Biogen study, officially t...
Biogen (BIIB) is back in focus after Chinese regulators accepted the Biologics License Application for a subcutaneous version of LEQEMBI, highlighting a potenti...